ArticleThe Journal of infection2020
Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient.
Article in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Isotyping and quantitation of the humoral immune response to SARS-CoV-2.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Equine immunoglobulin fragment F(ab')Clinical immunology (Orlando, Fla.) · 2022Article
- Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2.ImmunoHorizons · 2021Article
- Counselling for COVID-19 vaccine is necessary: Balancing the autonomy, beneficence and non-maleficence in the context of accelerating vaccine development.International journal of clinical practice · 2021Article
- Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein.Nature communications · 2021Article
- Article
- Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection.The Journal of infection · 2021Article
- Identifying New COVID-19 Receptor Neuropilin-1 in Severe Alzheimer's Disease Patients Group Brain Using Genome-Wide Association Study Approach.Frontiers in genetics · 2021Article
- Article
- COVID-19 Pandemic: Review of Contemporary and Forthcoming Detection Tools.Infection and drug resistance · 2021Review
- COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response.Vaccines · 2020Review
- Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike.Cell reports. Medicine · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We followed-up a mild COVID-19 patient for 91 days and serially monitored his serum antibodies to four SARS-CoV-2 related antigens (NP, RBD, S1 and ECD) and neutralization activities. Our data revealed a profile of serial antibody responses during the progress and a quick decline of neutralization activities after discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.